EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of canagliflozin on insulin sensitivity in insulin-dysregulated horses as assessed by euglycemic hyperinsulinemic clamp: a randomized, placebo-controlled trial

Elin Svonni iD, Peter Michanek iD, Peter Bergsten iD, Sanna Lindåse iD, Johan Bröjer iD

Journal of Veterinary Internal Medicine · 01.09.2026 · 40 (5)

DOI: 10.1093/jvimsj/aalag285 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Veterinary Internal Medicine, online erschienen am 29.10.2026. Verfasst von Elin Svonni und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden. Hauptthemen laut MEDLINE: Canagliflozin, Horse Diseases, Hypoglycemic Agents, Insulin Resistance. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Max Stenbeck Charitable Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Insulin resistance, enhanced β-cell responsiveness, and lower insulin clearance contribute to hyperinsulinemia in horses with insulin dysregulation. Canagliflozin (CAN) reduces hyperinsulinemia in horses, but its effect on insulin sensitivity (IS) remains unclear. Hypothesis/Objectives Evaluate the effects of CAN on IS and insulin clearance using a euglycemic hyperinsulinemic clamp (EHC) and on β-cell responsiveness using a graded glucose infusion test (GGI) in insulin-dysregulated (ID) horses. Animals Twenty privately owned ID mares.

Methods

In this randomized, double-blind, placebo-controlled study, horses received CAN (0.4 mg/kg, n = 10) or placebo (PBO, n = 10) PO once daily for 4 weeks. Insulin sensitivity and insulin metabolic clearance rate (MCR) were assessed by EHC, and β-cell responsiveness by GGI.

Results

Insulin sensitivity (M/I) was lower with CAN than PBO (1.5 ± 0.2 vs 2.7 ± 0.2 [mg/kg/min × 103]/[μIU/mL]; LS mean difference,—1.3 [95% CI, -1.9 to -0.6]; P < .001), whereas insulin MCR was higher (6.5 ± 0.3 vs 5.4 ± 0.3 mL/kg/min; LS mean difference, 1.0 [95% CI, 0.3-1.8]; P = .01). Beta-cell responsiveness (ΔI vs ΔG) was 43.3% lower with CAN (20.8 [95% CI, 16.9-25.5] vs 36.7 [29.9-45.1] mIU/mmol; ratio of geometric LS means, 0.57 [95% CI, 0.42-0.76]; P < .001). Conclusions and clinical importance Beta-cell responsiveness was lower and insulin clearance higher in CAN-treated ID mares, despite apparently lower IS. Higher endogenous glucose production in CAN-treated mares might have contributed to an underestimation of IS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinHorse DiseasesHypoglycemic AgentsInsulin ResistanceAnimalsFemaleBlood GlucoseDouble-Blind MethodGlucose Clamp TechniqueHorsesHyperinsulinismInsulinInsulin-Secreting Cells

Stichwörter der Autor:innen

SGLT2 inhibitorequineequine metabolic syndromehyperinsulinemiainsulin dysregulationsodium-glucose co-transporter 2 inhibitor

Substanzen

Blood GlucoseCanagliflozinHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden.
  • Department of Animal Biosciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden.
  • Department of Women's and Children's Health; Centre for Health and Sustainability, Uppsala University, 751 85 Uppsala, Sweden.

ORCID-Profile: Elin Svonni, Peter Michanek, Peter Bergsten, Sanna Lindåse, Johan Bröjer

Förderung

  • Max Stenbeck Charitable Fund

Zitieren

APA

Svonni, E., Michanek, P., Bergsten, P., Lindåse, S., & Bröjer, J. (2026). Effect of canagliflozin on insulin sensitivity in insulin-dysregulated horses as assessed by euglycemic hyperinsulinemic clamp: a randomized, placebo-controlled trial. Journal of Veterinary Internal Medicine, 40(5). https://doi.org/10.1093/jvimsj/aalag285

Vancouver

Svonni E, Michanek P, Bergsten P, Lindåse S, Bröjer J. Effect of canagliflozin on insulin sensitivity in insulin-dysregulated horses as assessed by euglycemic hyperinsulinemic clamp: a randomized, placebo-controlled trial. Journal of Veterinary Internal Medicine. 2026;40(5). doi:10.1093/jvimsj/aalag285

BibTeX
@article{Svonni2026,
  author = {Svonni, Elin and Michanek, Peter and Bergsten, Peter and Lindåse, Sanna and Bröjer, Johan},
  title = {Effect of canagliflozin on insulin sensitivity in insulin-dysregulated horses as assessed by euglycemic hyperinsulinemic clamp: a randomized, placebo-controlled trial},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2026},
  volume = {40},
  number = {5},
  doi = {10.1093/jvimsj/aalag285}
}
Kostenlos starten →